Cannabidiol or CBD is arguably one of the most significant chemical compounds in the medical world today. CBD which is extracted from the Cannabis plant has been heavily studied in recent years. And the wave of Cannabis legalization has even made CBD more popular. CBD has a host of medical benefits that researchers have been studying. Till date, CBD has been known to treat illnesses such as anxiety, insomnia, Parkinson’s disease, and epilepsy.
Recently, the Food and Drug Administration in the US approved a CBD-based drug for the treatment of seizure from epilepsy. Epidiolex is the name of the first CBD-based drug that the FDA approved. Epidiolex is manufactured by GW Pharmaceuticals which backed numerous studies backing this CBD-based drug.
Now GW Pharmaceuticals, a Cambridge-based company, is backing a study into a cannabis-based medicine for the treatment of Alzheimer’s disease. The study is in collaboration with Alzheimer’s Research UK. The UK is one of the few countries in Europe to have made medical cannabis legal.
Sativex is the name of the cannabis drug that GW Pharma is studying as a potential treatment for some symptoms of Alzheimer’s. Sativex is a Cannabis-based drug that is a mouth spray. Sativex contains CBD and THC in equal amounts. GW Pharma made headlines when Sativex became the first cannabis-based drug to be licensed by health authorities in the UK. Sativex is meant for the treatment of several symptoms of multiple sclerosis which include sleep disturbance, tremors, pain, and spasticity.
The study into using Sativex for the treatment of Alzheimer’s is at the clinical trial stage and is being conducted at King’s College in London. Statistics show that about 850,000 people in Britain are living with Alzheimer’s disease. These 850,000 people reportedly suffer from aggression and agitation. These two symptoms are some of the most challenging since they pose difficulties for patients with Alzheimer’s and people giving them care.
Alzheimer’s Research UK and GW Pharma have spent about £300,000 ($384,000) in the studies of Sativex for Alzheimer’s disease. Researchers are currently looking for volunteers living with dementia aged between 55 to 90. As a requirement, these volunteers must be experiencing the symptoms of agitation or aggression. The study will reportedly take about four weeks, and a larger clinical trial will be conducted if the research is successful and the symptoms of the recruits improve.
Researchers have a huge task of proving that this cannabis-based mouth spray can treat aggression and agitation in people with Alzheimer’s. However, researchers are optimistic; they point to the fact that it has been more than a decade since there has been a new medication for the treatment of Alzheimer’s.
The head of the Sativex study, Dr. David Reynolds said he is optimistic about the research. He said there is hope since researchers will employ novel methods and rigorous clinical.
The news of the study being conducted by GW Pharma and Alzheimer’s Research UK has welcomed many in the UK. The news of the study has caused an increase in the price share of GW Pharma share